TL;DR
- 1.Most injectable research peptides (BPC-157, TB-500, GHK-Cu) are too large to be CYP3A4 substrates. The enzyme interaction fears circulating in peptide communities are mostly misdirected.
- 2.GLP-1 peptides (semaglutide, tirzepatide) slow gastric emptying by up to 45 percent. Taking oral supplements at the same time dramatically reduces their absorption.
- 3.Berberine and GLP-1 peptides both lower blood glucose independently. Combined, they can push blood sugar dangerously low during a fasted injection window.
- 4.GHK-Cu delivers copper directly. Taking more than 40 mg of zinc per day blocks intestinal copper absorption and quietly undermines the copper economy your GHK-Cu protocol depends on.
- 5.St. John's Wort triples CYP3A4 activity and does not affect most research peptides directly, but it strips out every CYP3A4-sensitive medication in your stack.
Every peptide forum has a thread warning you about CYP3A4 blockers destroying your BPC-157 clearance. There is one problem: BPC-157 is a 15-amino-acid peptide with a molecular weight above 1,000 daltons. A 2025 review in Clinical and Translational Science analyzed every therapeutic peptide approved between 2021 and 2024 and found that peptides above 2 kilodaltons show minimal risk of clinically meaningful CYP interactions. BPC-157 is not cleared by your liver's CYP enzymes the way a statin is. The feared interaction is largely not happening.
But five interactions are. They are just completely different ones than the community talks about.
The molecular weight threshold above which therapeutic peptides show minimal CYP-mediated interaction risk, per a 2025 Clinical and Translational Science review of all peptides approved 2021 to 2024. Most injectable research peptides clear this threshold easily. Most people in peptide communities are worried about the wrong interactions.
Peptides interact with supplements through two mechanisms. Pharmacokinetic interactions change how fast a compound is cleared from your body. Pharmacodynamic interactions happen when two compounds hit the same biological target and compete or amplify each other.
For most injectable research peptides, pharmacokinetic CYP interactions are minimal because these peptides are primarily degraded by plasma proteases, not hepatic enzymes. The real risks are pharmacodynamic: two compounds fighting over the same receptor, enzyme, or mineral. One exception involves GLP-1 agonists, which have a documented indirect effect on everything you swallow.
Think of it this way. A small-molecule drug like atorvastatin passes through your liver's chemical processing plant (CYP enzymes) to be broken down. Blocking those enzymes lets the statin accumulate to toxic levels. Most research peptides skip the chemical plant entirely. They get cut into amino acid fragments by molecular scissors in your bloodstream (proteases). Blocking the chemical plant does nothing to the scissors. The five interactions below work through completely different mechanisms than CYP enzyme competition.
Which Supplement Pairings Actually Create Problems With Peptides?
1. Berberine + GLP-1 Peptides (Semaglutide, Tirzepatide)
Berberine is the most popular natural blood-glucose-lowering compound in the longevity and metabolic health community. If you are running semaglutide or tirzepatide and have added berberine to your stack, you have created two separate problems at once.
The first is pharmacodynamic. Both compounds lower blood glucose through different but complementary mechanisms. Semaglutide stimulates insulin secretion and suppresses glucagon. Berberine activates AMPK, improving insulin sensitivity through an entirely independent pathway. Together, they push blood sugar lower than either would alone. During a fasted morning injection window, this combination can drop glucose into hypoglycemic territory faster than you expect, particularly if you are also restricting carbohydrates.
The second issue is pharmacokinetic, and it applies to tirzepatide specifically. Tirzepatide is cleared partly via proteolytic cleavage and partly through pathways that include CYP enzyme contributions. Berberine is a moderate CYP3A4 inhibitor. In a slow CYP3A4 metabolizer who adds berberine, tirzepatide exposure can run measurably higher than the prescribing label assumes, amplifying both the GI side effect profile and the hypoglycemia risk from the first mechanism.
What to do: If you are running a GLP-1 peptide and want to keep berberine, separate them by 6 to 8 hours and monitor your blood glucose closely in the first week. Never combine them in a fully fasted state. See the CYP3A4 slow metabolizer guide to understand whether your genotype puts you at elevated risk for this specific combination.
2. Oral Supplements Taken Simultaneously With GLP-1 Peptides
This is the interaction most people are getting wrong every morning, and the FDA documented it explicitly in the Ozempic prescribing information.
Semaglutide slows gastric emptying by roughly 40 to 45 percent in the acute post-dose period. Everything you swallow in the hours after your injection moves through your gut at a significantly reduced rate. For most nutrients, this is a minor timing inconvenience. For specific oral supplements and medications with narrow absorption windows, it measurably reduces peak blood concentration.
The highest-risk co-administration is oral thyroid medication. The FDA Ozempic label explicitly calls out that slowed gastric emptying may reduce peak concentration of oral levothyroxine. The same logic applies to oral biotin, oral magnesium, fat-soluble vitamins, and any supplement whose therapeutic value depends on absorption kinetics. People taking GLP-1 peptides who add their full morning supplement stack at the same time then wonder why thyroid function or micronutrient markers look off. This is the mechanism.
"Semaglutide causes a delay in gastric emptying and may influence the absorption of concomitantly administered oral medications. Use with caution in patients taking oral medications where a threshold concentration is important for efficacy."
FDA Ozempic Prescribing Information, Drug Interactions, 2024
What to do: Take critical oral medications at least 30 to 60 minutes before your GLP-1 injection. For non-critical supplements, a 2-hour separation post-injection is a safe buffer. Review the oral peptide bioavailability guide for a fuller picture of how route of administration changes absorption math across the full peptide class.
3. High-Dose Zinc (Greater Than 40 mg Per Day) + GHK-Cu
GHK-Cu is glycine-histidine-lysine complexed with a copper ion. The copper is the active component. GHK serves as the delivery vehicle and tissue-targeting scaffold. Any protocol that depletes systemic copper will undermine what you are trying to accomplish with GHK-Cu.
High-dose zinc does exactly this. The NIH Office of Dietary Supplements documents that zinc intake above 40 mg per day inhibits intestinal copper absorption by inducing metallothionein in intestinal enterocytes. Metallothionein binds dietary copper and prevents its transfer into systemic circulation. The effect is dose-dependent and begins within a few weeks of sustained high-dose supplementation.
Many people running GHK-Cu for skin or anti-aging purposes are simultaneously taking 50 to 100 mg of zinc for immune support or testosterone optimization. They are delivering copper via the peptide while simultaneously blocking the gut's copper absorption at the enterocyte level. The result is a copper-depleted environment that partially defeats the purpose of the GHK-Cu protocol.
The 40 mg per day Tolerable Upper Intake Level from the National Academies is not a zinc toxicity threshold. It is specifically the level at which copper interference becomes clinically significant. This is a mineral transport competition, not a CYP enzyme issue, but the practical outcome is similar: the compound you are paying for is less effective because another supplement is interfering with its mechanism.
What to do: Keep zinc below 40 mg per day while running GHK-Cu. If higher zinc doses are therapeutically necessary, separate zinc and any copper-containing supplement by at least 2 hours and watch for copper deficiency markers (fatigue, brittle nails, anemia). Check the guide to metabolic pathway interactions for context on how mineral transport competition parallels enzyme-level interactions in its clinical significance.
4. NSAIDs or High-Dose Fish Oil + BPC-157
BPC-157's tissue healing mechanism involves prostaglandin signaling. Specifically, BPC-157 upregulates prostaglandin E2 and related eicosanoids that coordinate the controlled inflammatory phase of tissue repair. This is how the peptide triggers angiogenesis and tissue remodeling at injury sites.
NSAIDs (ibuprofen, naproxen, aspirin at anti-inflammatory doses) inhibit COX-1 and COX-2, the enzymes that produce prostaglandins. They do not merely reduce perceived pain at the injury site. They block the specific pro-healing prostaglandin signal that BPC-157 depends on to drive repair. Running ibuprofen daily while on a BPC-157 tendon or gut healing protocol puts two mechanisms in direct opposition.
Whether NSAID co-administration measurably reduces BPC-157 efficacy in controlled human trials has not been directly tested. The mechanistic conflict is real, however, and it is consistent with a well-established principle in sports medicine: systemic NSAIDs suppress the inflammatory signaling required for tissue regeneration. This is the same reason orthopedic surgeons advise against chronic NSAID use during tendon repair recovery.
Fish oil note: Standard omega-3 doses of 2 to 3 grams of EPA/DHA per day do not create this problem. Fish oil at therapeutic anti-inflammatory doses of 5 to 8 grams per day begins to inhibit prostaglandin synthesis at the COX level. If you are using high-dose fish oil specifically for its anti-inflammatory effect while running BPC-157 for tissue repair, you may be suppressing the healing cascade the peptide is trying to activate.
What to do: For pain management during a BPC-157 protocol, acetaminophen or topical diclofenac is a better choice than systemic COX inhibitors. If NSAIDs are unavoidable, use the lowest effective dose and avoid dosing them in the same 3-hour window as your BPC-157 injection. See the peptide dosing mistakes guide for additional protocol errors that reduce efficacy through mechanism conflicts rather than pharmacokinetic ones.
5. St. John's Wort + Any Stack That Includes CYP3A4-Sensitive Medications
St. John's Wort (Hypericum perforatum) is the most potent OTC CYP3A4 inducer available without a prescription. Hyperforin, its primary active constituent, upregulates CYP3A4 expression by two to four fold and simultaneously induces P-glycoprotein. This is one of the most extensively documented herb-drug interactions in clinical pharmacology, with the FDA and EMA both issuing formal guidance on the risk.
Here is the nuance the peptide community consistently misunderstands: St. John's Wort does not dramatically affect most injectable research peptides directly, because those peptides are not CYP3A4 substrates. They are cleared by plasma proteases, not hepatic enzymes. The problem is everything else in your stack.
People running peptide protocols typically have full concurrent supplement and medication stacks: statins, oral contraceptives, thyroid medication, antidepressants, immunosuppressants. All of these have meaningful CYP3A4-mediated clearance. Adding St. John's Wort creates a cascade: the SJW accelerates clearance of these medications far faster than the prescribing physician expects, therapeutic levels fall below efficacy thresholds, and the effect disappears. Your contraceptive fails. Your statin loses efficacy. Your antidepressant stops working. None of it shows up obviously in a chart review.
This is the "well, actually" correction most peptide content gets backwards. The community fears berberine blocking BPC-157 clearance (largely not a real problem for injectable peptides above 2 kDa). The real risk is St. John's Wort demolishing clearance of every CYP-sensitive medication in the stack that exists alongside the peptides.
How Your CYP Genotype Changes the Severity of Each Interaction
The five interactions above exist on a spectrum of severity. Interactions 1 and 2 are the most clinically significant for most users because they involve FDA-approved GLP-1 drugs with documented pharmacological effects on glucose and gut transit. Interactions 3, 4, and 5 are real but dose-dependent and highly variable between individuals.
Where genetics enters: your CYP3A4 metabolizer status determines your baseline clearance rate before you add any supplement at all. If you carry the CYP3A4 *22 allele, found in roughly 4 to 5 percent of people of European ancestry, your baseline CYP3A4 activity is already reduced by 30 to 40 percent compared to standard function. Adding a moderate inhibitor like berberine on top of that does not just reduce clearance a little. It compounds an already-reduced system. Two people on the same GLP-1 peptide plus berberine combination can have dramatically different outcomes: one barely notices the blood glucose effect, the other hits clinical hypoglycemia. The difference is often CYP genotype.
Fast metabolizers (carrying CYP3A4 ultra-rapid alleles) start from higher baseline clearance. Moderate inhibitors matter considerably less. St. John's Wort induction pushes their activity toward normal rather than into a hyperclearance zone that strips out medications they need.
For GHK-Cu and the zinc interaction, the relevant genetics are in metallothionein gene variants rather than CYP enzymes. People with high metallothionein inducibility experience greater copper sequestration at any given zinc dose. The same 50 mg zinc supplement that causes mild copper interference in one person can create significant copper depletion in another, depending on their MT gene expression profile.
| Supplement | Peptide affected | Mechanism | Severity | Fix |
|---|---|---|---|---|
| Berberine | Semaglutide, tirzepatide | Additive blood sugar lowering plus CYP3A4 inhibition | High (especially fasted) | Separate by 6 to 8 hours; monitor glucose in week 1 |
| Oral supplements at the same time as injection | All GLP-1 peptides | Gastric emptying delay reduces oral absorption | Moderate to high | Take oral meds 30 to 60 minutes before injection |
| High-dose zinc (over 40 mg per day) | GHK-Cu | Metallothionein induction blocks intestinal copper absorption | Moderate | Keep zinc below 40 mg; separate timing by 2 hours minimum |
| NSAIDs or high-dose fish oil (over 5 g EPA/DHA) | BPC-157 | COX inhibition suppresses prostaglandin-mediated healing signal | Moderate | Use acetaminophen instead; avoid NSAID overlap with BPC-157 dose |
| St. John's Wort | CYP-sensitive co-medications in the stack | CYP3A4 induction 2 to 4 fold accelerates clearance of sensitive medications | High if prescription meds present | Remove SJW from any stack that includes CYP3A4-sensitive medications |
Verdict: The CYP interactions the peptide community worries about, enzyme blocking that reduces BPC-157 or TB-500 clearance, are not the real problem for injectable research peptides.
The actual risks operate at the level of blood glucose additive effects, gut absorption timing, mineral transport competition, prostaglandin pathway antagonism, and medication clearance acceleration. If you are running GLP-1 peptides alongside berberine or taking your oral supplements right after injection, those are the two most urgent things to fix today. For GHK-Cu users: audit your zinc dose. For BPC-157 healing protocols: reconsider daily NSAID use during active protocol weeks. And if St. John's Wort is anywhere in a stack that includes prescription medications, remove it immediately. If you want to know how your CYP genotype, metallothionein variants, and metabolizer status change the specific risk profile for each of these interactions, upload your DNA data or order a saliva kit to get a personalized peptide report built around your actual pharmacogenomics.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Can you take berberine while on semaglutide or tirzepatide?
You can, but the combination requires careful management. Berberine and GLP-1 peptides both lower blood glucose through different mechanisms, and combined they can push blood sugar into hypoglycemic territory, especially in a fasted state. Berberine is also a moderate CYP3A4 inhibitor that may slow tirzepatide clearance and increase exposure above what the prescribing label assumes. If you want to use both, separate them by at least 6 to 8 hours and monitor your glucose closely in the first week of combining them.
Does BPC-157 interact with ibuprofen or NSAIDs?
There is a meaningful mechanistic conflict. BPC-157 drives tissue healing partly through prostaglandin E2 signaling. NSAIDs inhibit COX-1 and COX-2, the enzymes that produce prostaglandins. Running daily ibuprofen on a BPC-157 healing protocol may blunt the specific pathway the peptide is trying to activate. Direct human RCT data on this combination does not yet exist, but the mechanistic conflict is consistent with established sports medicine principles about NSAID suppression of tissue regeneration. For pain management during a BPC-157 protocol, acetaminophen or topical diclofenac is a better choice.
Does St. John's Wort affect peptides?
St. John's Wort does not dramatically affect most injectable research peptides directly, because those peptides are not CYP3A4 substrates. They are cleared by plasma proteases, not hepatic enzymes. The danger is indirect: St. John's Wort upregulates CYP3A4 by two to four fold and accelerates clearance of every CYP3A4-sensitive compound in your stack, including statins, oral contraceptives, thyroid medications, and antidepressants. If your peptide protocol runs alongside any of these medications, adding St. John's Wort can strip them below therapeutic levels without an obvious cause.
Can I take zinc supplements while running GHK-Cu?
High-dose zinc supplementation above 40 mg per day interferes with GHK-Cu by depleting systemic copper. The NIH Office of Dietary Supplements documents that zinc at this threshold induces metallothionein in intestinal enterocytes, which binds dietary copper and prevents its absorption into circulation. Since the copper in GHK-Cu is central to the peptide's mechanism, running high-dose zinc simultaneously creates a situation where you deliver copper via the peptide but block the broader copper economy at the gut level. Keep zinc below 40 mg per day while running GHK-Cu, or separate the doses by at least 2 hours.
Do research peptides actually go through CYP enzymes?
It depends on the peptide. Most injectable research peptides including BPC-157, TB-500, GHK-Cu, thymosin alpha-1, and ipamorelin are primarily cleared by proteolytic enzymes in the blood and tissues, not by hepatic CYP metabolism. A 2025 review in Clinical and Translational Science found that peptides above 2 kilodaltons generally present minimal CYP-mediated interaction risk. GLP-1 agonists like semaglutide and tirzepatide have more complex pharmacokinetics with greater CYP pathway contributions than typical research peptides, which is why the interaction rules differ significantly between these two groups.
How do I time my supplements if I take semaglutide or tirzepatide?
Take any critical oral medications or supplements at least 30 to 60 minutes before your GLP-1 injection. The FDA Ozempic prescribing information specifically calls this out for oral levothyroxine. In the acute post-dose window, semaglutide slows gastric emptying by up to 45 percent, which delays absorption of everything you take orally at the same time. For non-critical supplements, a 2-hour post-injection separation is a reasonable buffer. This timing rule applies whether you are injecting subcutaneously or taking oral semaglutide (Rybelsus).
Does my CYP genotype change how much supplement interactions affect me?
Yes, significantly. If you are a slow CYP3A4 metabolizer carrying the *22 allele, your baseline clearance is already reduced 30 to 40 percent compared to normal. Adding a CYP3A4 inhibitor like berberine on top of that compounds an already-suppressed system. The same berberine dose that causes negligible clearance changes in a fast metabolizer can create clinically meaningful exposure increases in a slow metabolizer. For St. John's Wort, the induction effect lands differently depending on your starting CYP activity level. Your metabolizer genotype is the variable that turns moderate supplement interactions into significant ones.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.